Last updated 2026-07-27
TL;DR
Topical dapsone (Aczone 5%/7.5%) has no fixed "cycle": most acne trials ran 12 weeks and dermatologists often keep patients on it for months to years as maintenance. Oral dapsone is a different drug with a different risk profile; courses are set by a prescriber, require G6PD-deficiency screening before starting, and involve regular bloodwork throughout because of hemolysis and methemoglobinemia risk.
What does "cycle length" even mean for dapsone?
There's no official "cycle" defined for dapsone the way there is for, say, a course of oral antibiotics for strep throat. The term gets used loosely online to mean two very different things, and mixing them up is where people get into trouble. For topical dapsone gel (brand name Aczone, 5% or 7.5%), there's no antibiotic-style stop date. It's a topical acne medication applied daily, and dermatologists generally treat it like other long-term acne therapies: you use it as long as it's working and tolerated, often for months at a stretch, sometimes for years as maintenance. For oral dapsone, which is a sulfone antibiotic used off-label for acne in some cases but more commonly prescribed for dermatitis herpetiformis, leprosy, and Pneumocystis jirovecii pneumonia prophylaxis, "cycle length" means something closer to a monitored course of therapy set by a physician, with lab checks built in at specific intervals [1][2]. These are not interchangeable products, and the FDA label reflects that difference directly. If you came here searching for how long to stay on "dapsone for acne," you almost certainly mean the topical gel. If you're on oral dapsone, that's a different conversation with different stakes, and it belongs to your prescriber, not a forum thread.
How long do people use topical dapsone (Aczone) for acne?
Most people use topical dapsone for months at a time, not weeks. The core FDA trials for Aczone 7.5% gel ran for 12 weeks, and that's the window most efficacy data comes from [3]. But 12 weeks was the study length, not a recommended stop point. In practice, once acne treatment starts working, dermatologists typically keep patients on it as part of an ongoing regimen, the same way they would with topical retinoids or benzoyl peroxide. Acne is a chronic condition for many people through their teens, twenties, and sometimes beyond, so "cycle length" often just means "as long as it keeps skin clear and you tolerate it." The original Aczone 7.5% gel clinical program (two identical 12-week, randomized, vehicle-controlled trials in patients 12 and older) found the treatment group achieved significantly greater reductions in inflammatory and noninflammatory lesions compared to vehicle gel, with the FDA approving it based on that data [3][4]. Long-term open-label extension data (up to 12 months) has also been collected for the drug, supporting continued use beyond the initial trial period for patients who respond [4]. A reasonable real-world approach: give it a full 8 to 12 weeks before judging whether it's working (acne treatments are slow), then continue indefinitely if it's helping and stop or adjust if it isn't. There's no medical need to cycle off it every few months the way you might with, say, a course of oral antibiotics for acne. If you want exact starting doses and application frequency, see Dapsone Rx dosage.
Is topical dapsone safe to use every day, long-term?
Yes, for most people. Topical dapsone's safety profile is a big part of why it's approved for long-term daily use in a way oral dapsone isn't. The most common side effects in trials were application-site dryness, redness, and peeling, generally mild [3]. A notable finding from the clinical program: unlike oral dapsone, topical dapsone gel does not require G6PD (glucose-6-phosphate dehydrogenase) deficiency screening before use. The FDA label states that in clinical trials, patients with G6PD deficiency who used Aczone gel did not show clinical evidence of hemolytic anemia, and hematologic changes were not clinically significant [1]. That's because very little of the drug is absorbed through the skin compared to swallowing a pill. This is the single most important distinction on this whole topic, so it's worth stating plainly: topical dapsone's low absorption is what makes it safe for long, unmonitored use. Oral dapsone's high absorption is what makes it dangerous without monitoring. Same drug molecule, completely different risk math depending on the route.
How long is a typical oral dapsone treatment course?
Oral dapsone courses vary widely by condition and are set entirely by the prescribing physician based on diagnosis, response, and lab results, not a fixed calendar. For dermatitis herpetiformis, treatment is often long-term, sometimes years, because the underlying gluten-sensitive condition tends to persist [2]. For Pneumocystis pneumonia prophylaxis in immunocompromised patients, it's typically continued as long as the immunosuppression risk remains [5]. For leprosy, multidrug regimens including dapsone commonly run 6 to 24 months depending on the WHO classification of disease and national treatment guidelines . There is no standard "acne cycle" for oral dapsone because oral dapsone is not FDA-approved for acne at all. Any oral dapsone acne use is off-label, and given the serious risks below, most dermatologists reach for it only when standard oral options (like doxycycline, spironolactone, or isotretinoin) aren't appropriate or haven't worked. Whatever the underlying condition, the pattern with oral dapsone is the same: start low, check labs, adjust, recheck. It's a monitored medical process, not a self-directed supplement schedule. For background on how the drug moves through the body and how that shapes dosing intervals, see Dapsone Rx half life.
Why does oral dapsone require G6PD testing before starting?
Because oral dapsone can cause severe, sometimes fatal hemolytic anemia in people with G6PD deficiency, an inherited enzyme deficiency that makes red blood cells more vulnerable to oxidative stress. G6PD deficiency affects an estimated 400 million people worldwide and is more common in people of African, Mediterranean, Middle Eastern, and Southeast Asian descent . The FDA prescribing information for oral dapsone states that hemolysis is dose-related and "patients with G6PD deficiency" are at increased risk, and that G6PD deficiency testing should be done before starting therapy . This isn't a minor precaution. Some degree of dose-related hemolysis occurs in most patients on oral dapsone even without G6PD deficiency, since red blood cells have a finite lifespan and dapsone's metabolites are oxidizing agents by nature; the question is how much, and G6PD-deficient patients can tip into dangerous territory fast [2]. This is exactly the point where people researching "dapsone for acne" online get confused, because they read about G6PD testing for oral dapsone and don't realize it doesn't apply to the topical gel most of them are actually asking about. Repeat it as many times as needed: topical Aczone does not require G6PD screening per its label; oral dapsone does [1].
What are the serious risks of oral dapsone during a treatment cycle?
Oral dapsone carries a real, named set of risks that topical dapsone essentially doesn't, and any conversation about "cycle length" for the oral drug has to include them. - Hemolytic anemia and methemoglobinemia: dose-related, more severe in G6PD-deficient patients, can present as fatigue, shortness of breath, pale or bluish skin, and dark urine .
- Agranulocytosis: a rare but serious drop in white blood cells, historically reported in roughly 1 in several thousand patients on dapsone, often appearing within the first few months of therapy, which is why early bloodwork matters so much [2].
- Dapsone hypersensitivity syndrome: a delayed, severe reaction (fever, rash, hepatitis, lymphadenopathy) typically appearing 2 to 6 weeks after starting the drug, with a mortality rate that has been reported around 9-10% in case reviews .
- Peripheral neuropathy: uncommon but documented with prolonged use, usually motor-predominant. Because dapsone hypersensitivity syndrome and agranulocytosis tend to show up in a specific early window, most prescribers front-load monitoring: baseline G6PD and CBC, then repeat CBC weekly or biweekly for the first month, tapering to monthly or less as things stabilize [2]. That monitoring schedule is really what defines the "cycle" of oral dapsone therapy, not a fixed number of weeks.
How is topical dapsone different from oral dapsone in terms of monitoring?
| FDA-approved use | Acne vulgaris [3] | Dermatitis herpetiformis, leprosy, PCP prophylaxis (off-label for acne) [1][2] | |
|---|---|---|---|
| G6PD testing required | Not required per label [1] | Recommended before starting | |
| Routine bloodwork | Not routinely required | CBC at baseline, then frequently (often weekly to biweekly) early in treatment [2] | |
| Typical "cycle" | Ongoing/maintenance, judged at 8-12 weeks | Set by prescriber per condition, often months to years, with monitoring checkpoints | |
| Major risks | Local dryness, mild irritation [3] | Hemolysis, methemoglobinemia, agranulocytosis, hypersensitivity syndrome | |
| Absorption | Minimal systemic absorption | Fully systemic (oral) | The table makes the point better than paragraphs can: these are two different risk categories wearing the same drug name. If your dermatologist prescribed the gel, you're in the low-monitoring column. If a physician prescribed oral dapsone tablets, you're in the high-monitoring column, and that's appropriate, not alarmist. |
Topical dapsone needs essentially no routine bloodwork for most users. Oral dapsone needs it consistently, especially early on. | | Topical dapsone (Aczone 5%/7.5%) | Oral dapsone |
What happens if you stop and restart a dapsone cycle?
For topical dapsone, stopping and restarting is low-stakes. Acne often creeps back over weeks to months if you stop an effective topical, since the medication controls the condition rather than curing it, similar to topical retinoids. Restarting typically just means resuming the same application routine; there's no re-induction period or special washout needed for the topical gel based on its labeling and studied use pattern [3]. For oral dapsone, restarting after a gap deserves the same caution as starting fresh. Because agranulocytosis and hypersensitivity reactions cluster in the early weeks of therapy, some clinicians treat a restart (especially after a gap of weeks or more) as a new monitoring period, repeating baseline labs rather than assuming the body will react the same way it did months ago [2]. This isn't universal practice, it's a judgment call your prescriber makes, but it's a reasonable one given how the hypersensitivity syndrome timeline works. If you're on oral dapsone and thinking about stopping or restarting on your own, that's a conversation to have with the prescriber first, not a decision to make solo based on how your skin looks that week.
How does dosing frequency affect how long a cycle feels?
Topical dapsone gel is typically applied once daily, and the 7.5% strength was specifically developed to allow once-daily dosing versus the original 5% gel's twice-daily regimen, based on the pharmacokinetic and efficacy data in its approval studies [4]. Once-daily use tends to mean better adherence over a long maintenance cycle, since twice-daily regimens are where people slip. Oral dapsone dosing varies by indication and is calculated by the prescriber based on body weight, diagnosis, and response, then adjusted based on lab results as the cycle progresses [2]. If you want a sense of how the numbers typically work for either form, Dapsone Rx dosage and the Dapsone Rx dosage calculator walk through the ranges people ask about most, and Dapsone Rx half life explains why oral dapsone's roughly 10 to 50 hour elimination half-life [2] shapes how spaced out doses and lab checks need to be.
Where does compounded or reconstituted dapsone fit into cycle length?
Some patients encounter dapsone in a compounded or reconstituted form rather than the standard manufactured gel or tablet, often through a specialty pharmacy. Cycle length in that context is still set by the prescriber's plan, not by the compounding format itself. What changes is practical: reconstituted formulations need to be mixed and stored correctly to hold their labeled concentration for the full course. Dapsone Rx works with patients through a provider-reviewed process and names the fulfilling pharmacy partner at the point of prescription, rather than compounding or manufacturing anything itself. If you've been prescribed a reconstituted version, the mixing steps matter for getting accurate dosing across the full cycle: see how to reconstitute Dapsone Rx for the practical steps, and Dapsone Rx how to inject and Dapsone Rx injection sites if your regimen involves an injectable form rather than the topical gel or oral tablet discussed here.
When should you talk to a doctor about starting or stopping a dapsone cycle?
Before starting topical dapsone, mention any other topical acne treatments you're using (benzoyl peroxide can cause temporary yellow/orange discoloration when combined with dapsone gel, a known but cosmetic interaction) [3]. There's no lab workup needed beforehand for most patients. Before starting oral dapsone, insist on G6PD testing if it hasn't already been discussed, and ask what the monitoring schedule will look like for the first month specifically, since that's when agranulocytosis and hypersensitivity syndrome are most likely to appear [2]. If you develop fever, sore throat, unusual bruising, yellowing skin, rash, or shortness of breath at any point during an oral dapsone cycle, that's a same-day call to the prescriber, not a wait-and-see situation. If you're getting either form through a provider-reviewed pathway like Dapsone Rx, the review step exists specifically to catch these distinctions before a prescription goes out, matching the right form of the drug and the right monitoring plan to your actual diagnosis.
Frequently asked questions
How long does a typical dapsone acne treatment cycle last?
For topical dapsone gel, there's no fixed end date; most people use it for months as ongoing maintenance, with the first real read on effectiveness at 8 to 12 weeks, matching the length of the core FDA trials. Oral dapsone (rarely used for acne) follows a prescriber-set schedule with lab monitoring instead of a set calendar length.
Do you need G6PD testing for topical dapsone gel?
No. The FDA label for Aczone states that G6PD-deficient patients in clinical trials showed no clinical evidence of hemolytic anemia using the topical gel, so routine G6PD screening isn't required for topical use. G6PD testing is specifically an oral dapsone requirement because of the drug's full systemic absorption when swallowed.
Can you use topical dapsone every day for years?
Yes, many dermatology patients do, since acne is often a chronic condition and topical dapsone's safety profile (mild dryness and irritation being the main side effects in trials) supports long-term daily use. There's no established maximum duration in the labeling; continuation depends on ongoing benefit and tolerance.
What is the difference between topical and oral dapsone risks?
Topical dapsone has minimal systemic absorption and mainly causes local skin irritation. Oral dapsone is fully absorbed and carries risks of hemolytic anemia, methemoglobinemia, agranulocytosis, and dapsone hypersensitivity syndrome, which is why oral use requires G6PD testing and regular bloodwork that topical use does not.
How often does bloodwork happen during an oral dapsone cycle?
Common practice is a baseline CBC and G6PD test before starting, then repeat CBC checks weekly to biweekly for the first month or so (when agranulocytosis risk is highest), spacing out to monthly or less once levels are stable. The exact schedule is set by the prescribing physician based on labs and symptoms.
Is oral dapsone FDA-approved for acne?
No. Oral dapsone is FDA-approved for dermatitis herpetiformis, leprosy (multidrug regimens), and Pneumocystis jirovecii pneumonia prophylaxis. Any use for acne is off-label and uncommon, generally reserved for cases where standard oral acne treatments aren't suitable, and it comes with the same hemolysis and monitoring requirements as any other oral dapsone use.
What are the symptoms of dapsone hypersensitivity syndrome?
Dapsone hypersensitivity syndrome typically appears 2 to 6 weeks after starting oral dapsone, with fever, a widespread rash, liver inflammation (hepatitis), and swollen lymph nodes. Case reviews report a mortality rate in the range of roughly 9 to 10%, which is why any fever-and-rash combination during an oral dapsone cycle needs urgent medical evaluation.
Can you stop topical dapsone and restart it later without issues?
Generally yes. Topical dapsone doesn't require a washout or re-induction period based on its studied use pattern; you resume the same daily application and acne control typically returns over the following weeks. Acne may return if you stop, since the gel manages the condition rather than curing it.
Why does oral dapsone require more monitoring than most antibiotics?
Because it causes dose-related oxidative stress on red blood cells in essentially everyone taking it, with more severe hemolysis in G6PD-deficient patients, plus separate risks of agranulocytosis and a delayed hypersensitivity syndrome that can be fatal. That combination of risks, not typically seen with drugs like doxycycline, is why oral dapsone needs G6PD testing and ongoing CBC checks.
How long until topical dapsone starts working for acne?
Clinical trials measured results at 12 weeks, and that's a reasonable timeline to judge real effect, though some improvement in inflammatory lesions can appear earlier. Acne treatments broadly are slow; stopping before 8 weeks because you don't see quick results is one of the most common reasons people quit before topical dapsone has a chance to work.
Does the 5% or 7.5% Aczone gel change the cycle length?
No, both strengths are used long-term the same way; the difference is dosing frequency, not duration. The 7.5% gel was developed for once-daily use versus the 5% gel's twice-daily regimen, based on the drug's pharmacokinetics and the approval studies, which can make it easier to stick with over a long maintenance period.
Who should not use oral dapsone at all?
People with known G6PD deficiency are at significantly higher risk of severe hemolytic anemia on oral dapsone and need explicit physician guidance before any use; some are advised against it entirely depending on severity. Anyone with a history of dapsone hypersensitivity syndrome or severe sulfone allergy should also avoid it. This decision belongs to a prescribing physician, not self-directed use.
Sources
- MedlinePlus, Dapsone (oral route): Oral dapsone uses, monitoring needs, and general dosing/duration guidance for dermatitis herpetiformis and other conditions
- CDC, Guidelines for Prevention and Treatment of Opportunistic Infections: Dapsone used for Pneumocystis jirovecii pneumonia prophylaxis, continued while immunosuppression risk remains
- World Health Organization, Guidelines for the Diagnosis, Treatment and Prevention of Leprosy: Multidrug therapy including dapsone for leprosy typically runs 6 to 24 months depending on disease classification
- CDC, Glucose-6-Phosphate Dehydrogenase (G6PD) Deficiency: G6PD deficiency prevalence and populations more commonly affected
- National Institutes of Health, StatPearls: Dapsone: Dapsone hypersensitivity syndrome timeline (2-6 weeks onset) and reported mortality rate around 9-10%